Arkolith/Insider Trading/ZYNE/Form 4

Anido Armando

Chairman & Chief Exec. Officer, DirectorZynerba Pharmaceuticals, Inc. (ZYNE) · full profile →Form 4 · filed Oct 11, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
6
5 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Oct 10, 2023Tender(U)567K——370K
Oct 10, 2023Grant(A)240K——610K
Oct 10, 2023Tender(U)610K——0
Oct 10, 2023Tender(U)27K——0
Oct 10, 2023Tender(U)13K——0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Oct 10, 2023Disposed to issuer(D)190K——0

Transaction Codes

U
See SEC Form 4 code table
A
Grant / award
D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001140361-23-047723) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML